Effectiveness of local ablative therapy combined with first-line tyrosine kinase inhibitors in epidermal growth factor receptor-mutated oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.
Rahul Bisht, Arusha Desai, Anjali Bhardwaj et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed local ablative therapy (LAT) plus first-line tyrosine kinase inhibitors (TKIs) versus TKI alone in patients with EGFR-mutated oligometastatic non-small cell lung cancer. Across 9 studies involving 1077 patients, combination treatment was associated with longer overall survival (HR 0.50; 95% CI 0.42-0.59; p < 0.001) and progression-free survival (HR 0.44; 95% CI 0.34-0.58; p < 0.001). The pooled analysis found no statistically significant difference in treatment-related toxicity between groups. The authors report that benefit was particularly apparent when LAT was used as consolidation therapy.
Key findings
- LAT plus TKI was associated with longer overall survival than TKI alone (HR 0.50; 95% CI 0.42-0.59; p < 0.001).
- Progression-free survival was longer with LAT plus TKI (HR 0.44; 95% CI 0.34-0.58; p < 0.001).
- Treatment-related toxicity risk did not differ statistically between treatment groups.
Why it matters
The findings suggest that treating limited metastatic sites alongside systemic EGFR inhibition may be associated with better disease control and survival, without a detected increase in toxicity. This is relevant when considering multimodality approaches for selected patients, while the pooled results should be interpreted in light of the underlying studies and their designs.
What to keep in mind
The abstract does not specify the designs or quality of the 9 included studies, limiting assessment of how well the pooled associations support causal conclusions.